The figure presents quantitative bacterial-growth trajectories for three bovine antimicrobial peptides—BMAP-28, Syn-1, and Bac-5—tested against the veterinary respiratory pathogen Mannheimia haemolytica. The reported curves compare peptide concentrations and starting bacterial burdens over time. In this study, inhibition depended on the candidate and exposure conditions, illustrating why a single endpoint cannot fully describe antimicrobial performance.1
The investigators also evaluated susceptibility endpoints and peptide combinations, demonstrating how isolate-level MIC/MBC measurements complement dynamic growth assessment. Separate published safety research shows that hemolysis can vary between host species, supporting the inclusion of species-relevant compatibility tests.2 Together, these findings inform practical study design for BioVenic's pathogen-panel screening, kinetic profiling, and preclinical lead-ranking services.